Abstract-The decline in glomerular filtration rate (GFR) associated with aging is one of the most important predisposing causes of kidney failure in old age. Identifying persons at risk for accelerated GFR decline is an essential first step in the development of preventive measures to preserve kidney function in the elderly. Heart rate (HR) has not yet been studied as a risk factor for GFR decline in the general population. In the RENIS-T6 (Renal Iohexol-Clearance Survey in Tromsø 6), we measured baseline ambulatory HR and GFR as iohexol clearance in a representative, middle-aged cohort of 1627 persons without self-reported diabetes mellitus, cardiovascular disease, or kidney disease. In the RENIS-FU (RENIS Follow-Up Study), we repeated the GFR measurements and calculated the rate of GFR decline in 81% of the participants after a median follow-up of 5.6 years. The unadjusted mean rate of GFR decline was 0.96 mL/ min per year. In multivariable-adjusted linear mixed models, 10 bpm higher ambulatory 24-hour and daytime HRs and office HR were associated with steeper GFR decline rates of 0.20 to 0.21 mL/min per year (P≤0.01). The odds ratio for predicting a rate of GFR decline twice that of the population mean in a fully adjusted model was 1.24 (P=0.01) for ambulatory 24-hour HR. Office HR was also an independent predictor of a steeper rate of GFR decline. HR may be a useful biomarker to identify persons at risk of accelerated GFR decline. (Hypertension. 2018;72:594-601.
T he prevalence of end-stage renal disease (ESRD) increases almost exponentially with increasing age. 1 Loss of functioning nephrons and decreased reserve capacity in old age increase the probability that acute kidney injury, comorbid conditions, nephrotoxic substances, or trauma may precipitate kidney failure. 2 However, there is considerable interindividual variation in the rate of age-related kidney function decline and in susceptibility to kidney failure. 3 Although a substantial part of this variation is caused by specific diseases, such as hypertension and diabetes mellitus, little is known about the risk factors for kidney function decline associated with aging. 4 The sympathetic nervous system is an important determinant of kidney function under normal conditions and has been shown to play an important role in animal models of kidney disease. 5 Aging is also accompanied by changes in the sympathetic nervous system, 6 suggesting that sympathetic dominance may play a role in age-related changes in kidney function.
Heart rate (HR) is a readily accessible indicator of sympathetic activity. Increased HR is an established risk factor for all-cause and cardiovascular mortality in the general population. 7 It is also an independent predictor of ESRD in highrisk cardiovascular patients 8 and in patients with established chronic kidney disease (CKD). 9 One study found an increased risk of ESRD with a higher resting HR and lower HR variability in the general population. 10 To our knowledge, no studies have been conducted to examine HR as a determinant of the mean rate of glomerular filtration rate (GFR) decline in the general population.
The aims of the present investigation were to study HR as a predictor of the rate of GFR decline as measured by iohexol clearance in a population-based cohort without significant comorbidities and to investigate its role in identifying persons with rapid GFR decline. We obtained HR data from 24-hour ambulatory blood pressure (ABP) recordings at baseline in the RENIS-T6 (Renal Iohexol-Clearance Survey in Tromsø 6) and repeated the iohexol clearance measurements in the RENIS-FU (RENIS Follow-Up Study).
Methods
The data that support the findings of this study are available from the corresponding author on reasonable request.
Study Population
The RENIS-FU is a follow-up of RENIS-T6, a substudy of the sixth Tromsø population survey.
11 RENIS-T6 included a representative sample of 1627 persons between 50 and 62 years of age from the general population without self-reported kidney disease, angina pectoris, myocardial infarction, stroke, or diabetes mellitus. The baseline GFR was measured by iohexol clearance between 2007 and 2009. Details have been described in a previous publication.
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All 1627 persons included at baseline were invited to participate in the RENIS-FU, except for 23 subjects who had died and 7 who had suffered possible delayed allergic reactions to iohexol, resulting in a total of 1597 eligible subjects. Of these, 1324 persons were examined at follow-up after a median observation period of 5.6 years, and 88 were randomly selected to have a repeated follow-up GFR measurement ( Figure) . Repeated measurements in a subsample were necessary for analysis with a linear mixed regression model with a random intercept and slope and an unstructured covariance matrix.
In the present investigation, the total cohort (n=1627) was used in all linear mixed model regression analyses because this method allows missing observations at one or more points in time. 12 The multiple logistic regression analyses of rapid GFR decline included the subset of subjects with follow-up measurements (n=1324). This study was approved by the Regional Committee for Medical and Health Research Ethics of North Norway and the Norwegian Data Inspectorate. The study adhered to the Declaration of Helsinki. All the subjects provided informed written consent.
Data
Both the baseline and follow-up investigations were conducted at the Clinical Research Unit of the University Hospital of North Norway. The assessments included a health questionnaire with questions about comorbidity, physical exercise, alcohol and tobacco use, and all current medications. Physical exercise was coded according to the following 3 categories: those who never exercised, those who exercised with low intensity (easy exercise without becoming breathless or sweaty) and those who exercised with high intensity (I push myself so hard that I become breathless or sweaty or I push myself to nearexhaustion). 13 Alcohol use was coded as 1 for alcohol use >2 to 4× a month and as 0 otherwise. Tobacco use was coded as the current number of cigarettes smoked daily.
Measurements

Iohexol Clearance
GFR was measured at baseline and during follow-up using singlesample plasma iohexol clearance. This method has been validated against gold standard methods. 14 The procedure used in the RENIS-FU was the same as that used in the RENIS-T6. 11, 15 The rate of GFR change was calculated as the follow-up GFR minus the baseline GFR divided by the time between the two. Accordingly, a negative change rate indicates a GFR decline.
HR and BP Measurements
ABP was measured using the Spacelab 90207 (Spacelab Inc, Redmond, WA). Ambulatory HR (AHR) and ABP were measured at 20-minute intervals from 0800 to 2200 hours and at 45-minute intervals from 2200 to 0800 hours. Persons with invalid measurements according to the criteria of the International Database on Ambulatory Blood Pressure in Relation to Cardiovascular Outcome study 16 had their measurements repeated as soon as possible, but the repeated attempt was unsuccessful in 17 persons. One person refused, and one person did not attend his/her scheduled second ABP measurement attempt. Thus, 1608 (99%) subjects had valid ABP measurements. The 19 missing measurements were imputed with multiple imputation (see Statistical Methods).
The mean AHR was calculated as the weighted mean of the measurements from 1000 to 2200 hours, and the mean nighttime AHR was calculated as the weighted mean of the measurements from midnight until 0600 hours. The measurements were weighted by the time interval between the readings. Twenty-four-hour AHR were calculated in the same way.
Office BP and HR (OHR) were measured 3× in a seated position by a trained study nurse after 2 minutes of rest with an automated device (model UA 799; A&D, Tokyo, Japan), with 1 minute between measurements. The average of the second and third HR measurements was used in the analyses.
Subjects with an office systolic BP ≥140 mm Hg, diastolic BP ≥90 mm Hg, or those who were on antihypertensive medications were categorized as having hypertension. The mean arterial pressure was estimated as diastolic BP plus one-third of the pulse pressure.
The ambulatory arterial stiffness index was calculated from a separate simple linear regression analysis of 24-hour systolic and diastolic ABP from each individual as described previously.
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Other Measurements
Baseline fasting serum glucose, insulin, triglycerides, LDL (lowdensity lipoprotein)-and HDL (high-density lipoprotein)-cholesterol, hemoglobin A1C, urinary albumin-creatinine ratio, and the homeostasis model assessment of insulin resistance were measured as described previously. [18] [19] [20] The waist circumference, serum thyroidstimulating hormone, high-sensitivity CRP (C-reactive protein), fibrinogen, hemoglobin, and leukocyte count were measured using standard methods in the main part of Tromsø 6 some months before the baseline examination in RENIS-T6.
Statistical Methods
Means (SDs) or medians (interquartile ranges) for skewed variables were used for descriptive statistics. Differences between subjects with 24-hour AHR greater or less than the median were tested with linear or median regression using the 24-hour AHR category as the independent variable, as appropriate.
Two approaches were used to investigate the influence of HR on GFR decline. First, the association between HR and the mean rate of GFR change was analyzed in linear mixed models with a random intercept and slope (n=1627). 12 Absolute GFR in mL/min was used as the dependent variable. Second, rapid decline in GFR was defined as a dichotomous variable corresponding to a rate of GFR change of at least twice that of the unadjusted population mean. This variable was analyzed in multiple logistic regression models for subjects examined at both baseline and follow-up (n=1324). See Methods in the online-only Data Supplement for a detailed discussion of the statistical methods.
Linear mixed and logistic regression analyses were adjusted for factors known or presumed to influence GFR or HR. Three models with stepwise addition of adjustment factors were used: model 1 (baseline GFR, age, sex, body weight, height, individual dichotomous variables for the use of antihypertensives [angiotensin-converting enzyme inhibitors, A2-receptor blockers, β-blockers, calcium blockers, thiazides, loop diuretics, aldosterone antagonists, and other antihypertensives] and other drugs which affect GFR or HR [nonsteroid anti-inflammatory drugs, thyroxine]); model 2 (the same variables as model 1 while also including LDL cholesterol, HDL cholesterol, fasting triglycerides, 24-hour mean arterial pressure, ambulatory arterial stiffness index, number of cigarettes currently smoked, hemoglobin A1c, urinary albumin-creatinine ratio, waist circumference and homeostasis model assessment of insulin resistance, and a dichotomous variable for the alcohol use); and model 3 (the same variables as model 2 while also including high-sensitivity CRP, fibrinogen, hemoglobin, leukocyte count, thyroid-stimulating hormone, and physical activity).
Some of the baseline variables had missing values. The percentage of missing data varied between 0.2% and 3.7% (Table S1 in 
Results
The baseline characteristics of the overall cohort (n=1627) according to the median 24-hour AHR are shown in Table 1 . The high AHR category comprised a greater number of women and persons classified as smokers, and fewer persons that exercised regularly, as well as persons who had a higher waist circumference, persons who demonstrated insulin resistance, and persons who had elevated urinary albumin-creatinine ratio (P<0.05). An increase was also seen in other markers of cardiovascular disease (CVD) risk (Table 1) . However, baseline GFR was not different across the AHR categories (P=0.25).
Mean Rate of GFR Changes
The unadjusted GFR declined more rapidly in the high AHR category than in the low AHR category ( Table 2) . We examined 24-hour, daytime, and nighttime AHRs as well as OHR in separate linear mixed models with stepwise additions of adjustments in the 3 models (n=1627; see Methods for full specification). In the fully adjusted models, 24-hour and daytime AHRs as well as OHR were all associated with a steeper rate of GFR decline by 0.20 to 0.21 mL/min per year (P<0.05; Table 3 ). The same analyses were repeated with generalized additive mixed models to study possible nonlinear relationships, but no such relationships were found. No statistically significant interactions between sex and HR were found for any of the HR types. When GFR adjusted for body surface area in mL/min per 1.73 m 2 was substituted for absolute GFR in mL/min as the dependent variable, the results were essentially equivalent to those in Table 3 .
To test the robustness of the associations, we repeated linear mixed regressions in the fully adjusted model for subgroups of persons without β-blocker use at baseline (n=72), without baseline hypertension (n=694), and without baseline CKD (GFR <60 mL/min per 1.73 m 2 or an urinary albumin-creatinine ratio >3.4 mg/mmol; n=73). To examine the possibility that the association between HR and GFR decline was caused by incident CVD during the observation period, we repeated the analyses after exclusion of all persons with self-reported CVD (angina pectoris, myocardial infarction, stroke, or other treated occlusive arterial disease; n=70) at follow-up. The results in these subgroups were very similar to those in the total cohort. We also repeated the analyses with OHR measured in the main part of the sixth Tromsø Study at a median of 5.2 months (interquartile range, 3.0-6.2) before the baseline examination in this study; these analyses revealed an attenuated but statistically significant association with GFR decline.
Risk of Rapid GFR Decline
We investigated the risk of rapid GFR decline defined as a rate of change less than twice the population mean (<−1.9 mL/min per year) in multiple logistic regression models with the same adjustments as those in the linear mixed models (n=1324; Table 4 ). All HR types were associated with a higher risk of rapid decline (yes/no) in all 3 models, except for the association of daytime HR in the fully adjusted model (P=0.05). All the models were well calibrated, as judged by the Hosmer-Lemeshow statistic and inspection of the calibration plots. Results concerning discrimination and reclassification can be found in the onlineonly Data Supplement (Tables S2 and S3) .
Discussion
This study found that HR, perhaps the least invasive and most easily accessible cardiovascular biomarker, was an independent predictor of GFR decline in a low-risk general population cohort. Compared with the mean population GFR decline of 0.96 mL/min per year, a steeper decline of 0.21 mL/min per year per 10 bpm higher 24-hour AHR is a clinically important effect. OHR measured with an automated BP measurement under standardized conditions demonstrated a similar association. The results remained robust after exclusion of persons with CVD at follow-up. Therefore, the development of CVD during the study period is unlikely to explain the results. To our knowledge, HR has not previously been investigated as a possible risk factor for GFR decline in the general population. HR was not considered in a recent study of ESRD risk among potential living kidney-donor candidates in a large study of general population cohorts. 21 However, Brotman et al 10 found an association between increased HR and risk of ESRD in the ARIC (Atherosclerosis Risk in Communities) Study. Furthermore, Inoue et al 22 demonstrated an increased risk of CKD, defined as an estimated The RENIS-FU study. A negative change rate signifies a fall in GFR between baseline and follow-up. GFR indicates glomerular filtration rate; and RENIS-FU study, Renal Iohexol-Clearance Survey Follow-Up Study.
*Median ambulatory 24-h heart rate is 69.8 bpm. †P value for difference across the 2 categories of ambulatory 24-h heart rate. The RENIS-FU study. Data are shown as mean (SD), median (interquartile range), or n (percent). ACE indicates angiotensin-converting enzyme; CRP, C-reactive protein; GFR, glomerular filtration rate; HDL, high-density lipoprotein; HOMA-IR, homeostasis model assessment of insulin resistance; LDL, low-density lipoprotein; and RENIS-FU study, Renal Iohexol-Clearance Survey Follow-Up Study.
*Median ambulatory 24-h heart rate is 69.8 bpm. †P value for difference across the 2 categories of ambulatory 24-h heart rate. ‡Office systolic blood pressure ≥140 mm Hg, office diastolic blood pressure ≥90 mm Hg, or the use of antihypertensive medications. 8 found that increased HR was a risk factor for ESRD or doubling of creatinine. Our results extend these findings by showing that high HR is also associated with an accelerated mean population GFR decline.
CKD is associated with an imbalance between the sympathetic and parasympathetic nervous systems. 23 Increased activity of the sympathetic nervous system with aging is one possible mechanism for the association between HR and GFR decline. 6 The sympathetic nervous system plays an important role in early phases of CKD. 24 Animal studies of CKD have found that renal denervation normalizes sympathetic nervous activity and improves GFR. 25 Human studies have found that renal denervation increases Na excretion 26 and reduces albuminuria and the renal arterial resistive index. 27 Nighttime AHR also predicted rapid GFR decline (Table 4 ) but was not statistically significant for predicting the mean GFR change rate (Table 3) . Because the CI for the β-coefficient was wide in the fully adjusted model, it is not possible to say whether this reflects a real difference from the other measures of HR.
The most important strength of our study was that the GFR was measured as iohexol clearance, which avoids confounding from non-GFR-related factors that influence the GFR estimated from creatinine or cystatin C. 28, 29 Additionally, the mean The RENIS-FU study. Separate analyses were performed for each category of heart rate. A negative β-coefficient signifies a steeper decline in GFR. GFR indicates glomerular filtration rate; and RENIS-FU study, Renal Iohexol-Clearance Survey Follow-Up Study.
*Model 1 adjusted for baseline GFR, age, sex, body weight, height, individual dichotomous variables for the use of antihypertensives (angiotensin-converting enzyme inhibitors, A2-receptor blockers, β-blockers, calcium blockers, thiazides, loop diuretics, aldosterone antagonists, and other antihypertensives), nonsteroid anti-inflammatory drugs and thyroxine.
†Adjusted as model 1 and in addition LDL (low-density lipoprotein)-cholesterol, HDL (high-density lipoprotein)-cholesterol, fasting triglycerides, mean 24 h-ambulatory mean arterial pressure, ambulatory arterial stiffness index, number of cigarettes currently smoked, hemoglobin A1c, urinary albumin-creatinine ratio, waist circumference and homeostasis model assessment of insulin resistance, and a dichotomous variable for the weekly use of alcohol or not.
‡Adjusted as model 2 and in addition high-sensitivity CRP (C-reactive protein), fibrinogen, hemoglobin, leukocyte count, thyroid-stimulating hormone, and physical activity. The RENIS-FU study. Rapid GFR decline defined as GFR change rate <−1.9 mL/min per year, that is, twice the cohort mean. Separate analyses were performed for each category of heart rate. GFR indicates glomerular filtration rate; and RENIS-FU study, Renal Iohexol-Clearance Survey Follow-Up Study.
†Adjusted as model 1 and in addition LDL (low-density lipoprotein)-cholesterol, HDL (high-density lipoprotein)-cholesterol, fasting triglycerides, mean 24-h ambulatory mean arterial pressure, ambulatory arterial stiffness index, number of cigarettes currently smoked, hemoglobin A1c, urinary albumin-creatinine ratio, waist circumference and homeostasis model assessment of insulin resistance, and a dichotomous variable for the weekly use of alcohol or not.
‡Adjusted as model 2 and in addition high-sensitivity CRP (C-reactive protein), fibrinogen, hemoglobin, leukocyte count, thyroid-stimulating hormone, and physical activity.
24-hour HR is likely a better measure of HR than short ECG recordings used in other studies of HR. 10, 16, 22, 26 The use of AHR reduces confounding because of possible stress-induced elevations in HR at the time of GFR measurement. To the best of our knowledge, our study is unique in combining these accurate measurements in a population study. We were also able to adjust the analyses for the most important determinants of HR, for example, physical activity, specific classes of important chronotropic drugs, and variation in thyroid function and hemoglobin concentration, to reduce the possibility of confounding. Finally, we excluded persons with prevalent CVD to avoid influences from heart failure and other heart disease.
The main limitation of the study was the lack of HR variability data based on ECG recordings. The inclusion of only middle-aged whites limits the possibility of generalizing our results to other ethnic and age groups. About HR as a diagnostic marker, we are not aware of other cohorts with repeated GFR measurements that could have provided external validation of our results. We also acknowledge that inferences about causality cannot be made from an observational study.
Perspectives
Both ambulatory and office HR are independent biomarkers for accelerated GFR decline in the general middle-aged population. Further research should aim to explore the mechanisms for this relationship. HR should be considered for inclusion in risk prediction models for rapid GFR decline in the general population.
